Приказ основних података о документу
Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report
dc.creator | Lijeskić, Olivera | |
dc.creator | Klun, Ivana | |
dc.creator | Stamenov Đaković, Marija | |
dc.creator | Gligorić, Nenad | |
dc.creator | Štajner, Tijana | |
dc.creator | Srbljanović, Jelena | |
dc.creator | Đurković-Đaković, Olgica | |
dc.date.accessioned | 2021-10-25T10:12:24Z | |
dc.date.available | 2021-10-25T10:12:24Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 2076-393X | |
dc.identifier.uri | http://rimi.imi.bg.ac.rs/handle/123456789/1168 | |
dc.description.abstract | Real-life data on the performance of vaccines against SARS-CoV-2 are still limited. We here present the rates of detection and levels of antibodies specific for the SARS-CoV-2 spike protein RBD (receptor binding domain) elicited by four vaccines available in Serbia, including BNT-162b2 (BioNTech/Pfizer), BBIBP-CorV (Sinopharm), Gam-COVID-Vac (Gamaleya Research Institute) and ChAdOx1-S (AstraZeneca), compared with those after documented COVID-19, at 6 weeks and 3 months post first vaccine dose or post-infection. Six weeks post first vaccine dose, specific IgG antibodies were detected in 100% of individuals fully vaccinated with BNT-162b2 (n = 100) and Gam-COVID-Vac (n = 12) and in 81.7% of BBIBP-CorV recipients (n = 148), while one dose of ChAdOx1-S (n = 24) induced specific antibodies in 75%. Antibody levels elicited by BNT-162b2 were higher, while those elicited by BBIBP-CorV were lower, than after SARS-CoV-2 infection. By 3 months post-vaccination, antibody levels decreased but remained ≥20-fold above the cut-off in BNT-162b2 but not in BBIBP-CorV recipients, when an additional 30% were seronegative. For all vaccines, antibody levels were higher in individuals with past COVID-19 than in naïve individuals. A total of twelve new infections occurred within the first 3 months post-vaccination, eight after the first dose of BNT-162b2 and ChAdOx1-S (one each) and BBIBP-CorV (six), and four after full vaccination with BBIBP-CorV, but none required hospitalization. | |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200015/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Vaccines | |
dc.subject | BBIBP-CorV | |
dc.subject | BNT-162b2 | |
dc.subject | ChAdOx1-S | |
dc.subject | COVID-19 | |
dc.subject | Gam-COVID-Vac | |
dc.subject | SARS-CoV-2 | |
dc.subject | specific antibodies | |
dc.subject | vaccine effectiveness | |
dc.title | Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report | |
dc.type | article | |
dc.rights.license | BY | |
dc.citation.issue | 9 | |
dc.citation.spage | 1031 | |
dc.citation.volume | 9 | |
dc.identifier.doi | 10.3390/vaccines9091031 | |
dc.identifier.fulltext | http://rimi.imi.bg.ac.rs/bitstream/id/2516/Prospective_Cohort_Study_of_the_Kinetics_pub_2021.pdf | |
dc.type.version | publishedVersion |